162 related articles for article (PubMed ID: 33050286)
1. Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients.
Augustin T; Oliinyk D; Köhler VF; Rauch J; Belka C; Spitzweg C; Käsmann L
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050286
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis.
Oliinyk D; Augustin T; Koehler VF; Rauch J; Belka C; Spitzweg C; Käsmann L
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32899355
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of radiotherapy for anaplastic thyroid cancer.
Park JW; Choi SH; Yoon HI; Lee J; Kim TH; Kim JW; Lee IJ
Radiat Oncol J; 2018 Jun; 36(2):103-113. PubMed ID: 29983030
[TBL] [Abstract][Full Text] [Related]
4. Radiation to the Primary Tumor in Metastatic Anaplastic Thyroid Cancer.
Augustin T; Oliinyk D; Rauch J; Koehler VF; Spitzweg C; Belka C; KÄsmann L
In Vivo; 2021; 35(1):461-465. PubMed ID: 33402497
[TBL] [Abstract][Full Text] [Related]
5. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic thyroid cancer in young patients: a contemporary review.
Li M; Milas M; Nasr C; Brainard JA; Khan MJ; Burkey BB; Scharpf J
Am J Otolaryngol; 2013; 34(6):636-40. PubMed ID: 23993450
[TBL] [Abstract][Full Text] [Related]
7. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.
Chintakuntlawar AV; Rumilla KM; Smith CY; Jenkins SM; Foote RL; Kasperbauer JL; Morris JC; Ryder M; Alsidawi S; Hilger C; Bible KC
J Clin Endocrinol Metab; 2017 Jun; 102(6):1943-1950. PubMed ID: 28324060
[TBL] [Abstract][Full Text] [Related]
8. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
[TBL] [Abstract][Full Text] [Related]
9. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.
Pezzi TA; Mohamed ASR; Sheu T; Blanchard P; Sandulache VC; Lai SY; Cabanillas ME; Williams MD; Pezzi CM; Lu C; Garden AS; Morrison WH; Rosenthal DI; Fuller CD; Gunn GB
Cancer; 2017 May; 123(9):1653-1661. PubMed ID: 28026871
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy.
Haefner MF; Lang K; Krug D; Koerber SA; Uhlmann L; Kieser M; Debus J; Sterzing F
J Radiat Res; 2015 Jul; 56(4):742-9. PubMed ID: 25907360
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma.
Akaishi J; Sugino K; Kitagawa W; Nagahama M; Kameyama K; Shimizu K; Ito K; Ito K
Thyroid; 2011 Nov; 21(11):1183-9. PubMed ID: 21936674
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes in Anaplastic Thyroid Cancer.
Corrigan KL; Williamson H; Elliott Range D; Niedzwiecki D; Brizel DM; Mowery YM
J Thyroid Res; 2019; 2019():8218949. PubMed ID: 31249658
[TBL] [Abstract][Full Text] [Related]
14. Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.
Prasongsook N; Kumar A; Chintakuntlawar AV; Foote RL; Kasperbauer J; Molina J; Garces Y; Ma D; Wittich MAN; Rubin J; Richardson R; Morris J; Hay I; Fatourechi V; McIver B; Ryder M; Thompson G; Grant C; Richards M; Sebo TJ; Rivera M; Suman V; Jenkins SM; Smallridge RC; Bible KC
J Clin Endocrinol Metab; 2017 Dec; 102(12):4506-4514. PubMed ID: 29029287
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors.
Kebebew E; Greenspan FS; Clark OH; Woeber KA; McMillan A
Cancer; 2005 Apr; 103(7):1330-5. PubMed ID: 15739211
[TBL] [Abstract][Full Text] [Related]
16. Lung cavitation in patients with anaplastic thyroid cancer treated with lenvatinib.
Murayama D; Yamamoto Y; Matsui A; Yasukawa M; Okamoto S; Toda S; Iwasaki H
Gland Surg; 2022 Jun; 11(6):963-969. PubMed ID: 35800737
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
Rao SN; Zafereo M; Dadu R; Busaidy NL; Hess K; Cote GJ; Williams MD; William WN; Sandulache V; Gross N; Gunn GB; Lu C; Ferrarotto R; Lai SY; Cabanillas ME
Thyroid; 2017 May; 27(5):672-681. PubMed ID: 28068873
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Survival in Patients Treated with Multimodal Therapy for Anaplastic Thyroid Cancer.
Käsmann L; Bolm L; Janssen S; Rades D
Anticancer Res; 2016 Sep; 36(9):4697-700. PubMed ID: 27630315
[TBL] [Abstract][Full Text] [Related]
19. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
20. Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients.
Ahn J; Song E; Oh HS; Song DE; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Jun; 29(6):824-829. PubMed ID: 30864902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
